Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
This study has been completed.
Prologue Research International
Information provided by:
First received: September 13, 2005
Last updated: January 8, 2010
Last verified: January 2010
This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy. This study will evaluate the safety and preliminary efficacy of the combination of lenalidomide and DTIC. Subjects will be receive lenalidomide for 14 consecutive days and DTIC on day one of each 21 day cycle.
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Primary Outcome Measures:
- To determine MTD of intravenous DTIC during the first 2 cycles (6 wks) of treatment
Secondary Outcome Measures:
- To evaluate the safety profile of combination lenalidomide plus DTIC, the preliminary efficacy of combination lenalidomide plus DTIC
- To define the recommended phase II doses of lenalidomide and DTIC when administered as combination therapy.
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2007 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Understand and voluntarily sign an informed consent document
- Age greater than or equal to 18 years at the time of signing Informed Consent
- Be able to adhere to the study visit schedule and other protocol requirements
- Histological documentation of malignant melanoma with evidence of metastatic disease
- For the 10 patients enrolled at the MTD, at least one measurable lesion must be present (see Appendix II)
- ECOG performance status of 0, 1 or 2 (see Appendix I)
Laboratory tests within these ranges:
- Absolute neutrophil count greater than or equal to 1,500/uL
- Platelet count greater than or equal to 100,000/uL
- Serum creatinine less than or equal to 1.5 mg/dL
- Total bilirubin less that or equal to 1.5 mg.dL
- AST (SGOT) / ALT (SGPT) less than or equal to to 2 times upper limit of normal (ULN)
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
In addition, sexually active WCBP must agree to use at least two methods of adequate contraceptive (oral, injectable, or implantable hormonal contraceptive, tubal ligation, intra-uterine device, barrier contraceptive with spermicide, contraceptive skin patch or vasectomized partner) while on study drug
- All acute adverse effects (excluding alopecia of any prior therapy must have resolved to less than or equal to grade 1 (NCI CTCAE v3.0)
- Patients must be able to take medications orally
- Pregnant or lactating females
- Any serious medical condition, including psychiatric illnesses that will prevent the patient from signing the informed consent or place the patient at an unacceptable risk if he/she participates in the study.
Prior treatment with systemic chemotherapy. Patients who have received prior immunotherapy, including thalidomide, or radiotherapy remain eligible.
Lesions within a prior field of radiation may only be used as indicator lesions if there has been evidence of disease progression at that site.
- Prior history of malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been free of the disease for at least 3 years.
- Use of thalidomide or biologic response modifier therapy within 14 days of Day 1, Cycle 1
- Prior greater than or equal to grade 2 allergic reaction to thalidomide
- Prior desquamating rash while taking thalidomide
- Any prior use of lenalidomide
- Concurrent use of any other anti-cancer agents
- Radiation or surgical treatment of melanoma within 28 days of starting study treatment
- Active infection
- Central nervous system (CNS) metastases
- Patients with > grade-2 neuropathy
- Patients with known HIV positivity or AIDS-related illness
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179608
|MD Anderson Cancer Center
|Houston, Texas, United States, 77030-4009 |
Prologue Research International
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 13, 2005
||January 8, 2010
||United States: Food and Drug Administration
Keywords provided by Celgene Corporation:
Metastatic Malignant Melanoma
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 27, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Angiogenesis Modulating Agents
Physiological Effects of Drugs